Dosing and uses of ATNAA, DuoDote (atropine-pralidoxime)
Auto-Injector System
2.1 mg atropine/0.7 mL + 600 mg pralidoxime/2 mL IM into outer thigh or buttocks
Other Indications & Uses
ATNAA (Antidote Treatment-Nerve Agent, Auto-Injector): anticholinesterase organophosphate nerve gas poisoning (Sarin, Tabun etc), available to military personnel only
Duodote: anticholinesterase organophosphate nerve gas/insecticide poisoning available to civilian emergency workers
Pediatric dosage forms and strengths
Safety and efficacy not established
ATNAA, DuoDote (atropine-pralidoxime) adverse (side) effects
Frequency not defined
Injection site pain
Flushing
Urinary retention
Hypertension
Asystole
Palpations
Anaphylaxis
Closed angle glaucoma
Warnings
No absolute contraindications
Pregnancy and lactation
Pregnancy category: C
Lactation: excretion in milk unknown; use with caution
Pregnancy categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA: Information not available.
